Human Mena (hMENA), an actin regulatory protein of the ENA/VASP family, cooperates with ErbB receptor family signaling in breast cancer. It is overexpressed in high-risk preneoplastic lesions and in primary breast tumors where it correlates with HER2 overexpression and an activated status of AKT and MAPK. The concomitant overexpression of hMENA and HER2 in breast cancer patients is indicative of a worse prognosis. hMENA is expressed along with alternatively expressed isoforms, hMENA 11a and hMENAΔv6 with opposite functions. A novel role for the epithelial-associated hMENA 11a isoform in sustaining HER3 activation and pro-survival pathways in HER2-overexpressing breast cancer cells has been identified by reverse phase protein array and validated in vivo in a series of breast cancer tissues. As HER3 activation is crucial in mechanisms of cell resistance to PI3K inhibitors, we explored whether hMENA 11a is involved in these resistance mechanisms. The specific hMENA 11a depletion switched off the HER3-related pathway activated by PI3K inhibitors and impaired the nuclear accumulation of HER3 transcription factor FOXO3a induced by PI3K inhibitors, whereas PI3K inhibitors activated hMENA 11a phosphorylation and affected its localization. At the functional level, we found that hMENA 11a sustains cell proliferation and survival in response to PI3K inhibitor treatment, whereas hMENA 11a silencing increases molecules involved in cancer cell apoptosis. As shown in three-dimensional cultures, hMENA 11a contributes to resistance to PI3K inhibition because its depletion drastically reduced cell viability upon treatment with PI3K inhibitor BEZ235. Altogether, these results indicate that hMENA 11a in HER2-overexpressing breast cancer cells sustains HER3/AKT axis activation and contributes to HER3-mediated resistance mechanisms to PI3K inhibitors. Thus, hMENA 11a expression can be proposed as a marker of HER3 activation and resistance to PI3K inhibition therapies, to select patients who may benefit from these combined targeted treatments. hMENA 11a activity could represent a new target for antiproliferative therapies in breast cancer.
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INTRODUCTION
Members of the ErbB family have a crucial role in breast cancer (BC) formation and progression. Identification of the mechanisms involved in their complex signaling network has led to the development of ErbB-specific inhibitors 1 that have improved the outcome of patients with HER2-positive tumors; however, a number of patients develop resistance to these drugs. One of the proposed resistance mechanisms involves reactivation of PI3K signaling via alternative receptor tyrosine kinase amplified pathways and/or mutations in the PI3K pathway. 2 Several antagonists of the PI3K pathway have been entered in phase I and II clinical trials. 3 However, their clinical efficacy is strongly impaired by compensatory feedback mechanisms that lead to upregulation and activation of multiple receptor tyrosine kinase and, finally, to drug resistance. 4, 5 HER3 is a critical signaling node in the ErbB family and its activation contributes to cellular adaptation to PI3K inhibitors in HER2-overexpressing tumors. [5] [6] [7] In HER2-driven cancers, HER3 is an important heterodimer partner that binds the PI3K regulatory subunits and activates the PI3K/AKT survival pathway, [8] [9] [10] suggesting that the co-inhibition of HER3 and PI3K pathways may exert a greater antitumor efficacy. 7 Actin cytoskeleton and its organization are strongly deregulated in cancer and affect many signaling pathways related to relevant cell functions, such as apoptosis, adhesion and migration. 11 Human MENA (hMENA) belongs to the ENA/VASP protein family with key roles in cellular processes governed by the actin dynamics. 12, 13 hMENA, overexpressed in 70% of BC with HER2+, ER/PgR − and high Ki67 phenotype and correlated with an activated status of MAPK and AKT kinases, has been reported as an early marker of breast tumorigenesis. 14, 15 The concomitant overexpression of HER2 and hMENA identifies a subgroup of BC patients with a worse prognosis. 15 The MENA gene encodes the 570-aa hMENA protein and different splicing-derived isoforms have been reported in human 16, 17 and mouse. 12, 18, 19 Two isoforms, epithelial specific hMENA 11a and mesenchymal specific hMENAΔv6, with opposing regulatory functions in tumor cell invasion are differently expressed in primary BC. 20 hMENA and hMENA 11a are upregulated by epidermal growth factor (EGF) and Neuregulin (NRG-1) growth factor that specifically phosphorylate hMENA 11a , whereas Trastuzumab treatment downregulates hMENA expression and inhibits hMENA 11a phosphorylation.
cell proliferation. 15 Given the role of hMENA 11a isoform in tumor cell proliferation and its cross talk with ErbB receptors, 15 we set up a phospho-proteomic analysis to investigate the role of hMENA 11a in different oncogenic signaling pathways related to proliferation and survival. Here, we show that the hMENA 11a overexpression correlates with HER3 and P-HER3 in HER2-overexpressing BC tissues. In HER2+ BC cells, our results indicate that hMENA 11a is an anti-apoptotic regulator involved in the HER3-mediated mechanisms of resistance to PI3K inhibition.
RESULTS
RPPA analysis reveals that hMENA 11a silencing inhibits HER3/AKT activation in MDA-MB-361 cells To examine the role of hMENA 11a overexpression on oncogenic signaling pathways related to cell proliferation and survival, we set up a reverse phase protein array (RPPA) analysis of 85 proteins and phospho-proteins (Supplementary Figure 1) . We compared the phospho-proteomic profiles of the luminal BC cell line MDA-MB-361, which overexpresses HER2 and hMENA/hMENA 11a , before and after hMENA 11a -specific silencing (MDA-MB-361 si-CNTR vs MDA-MB-361 si-hMENA 11a ). The hMENA 11a silencing specifically downregulates the hMENA 11a protein level, but does not modify the hMENA protein level (Supplementary Figure 2) . The heatmap in Figure 1a shows the hierarchical clustering of 59 significant endpoints; MDA-MB-361 control cells displayed a sustained activation of several oncogenic pathways, for example, HER2 and EGFR, and a moderate activation of HER3. hMENA 11a silencing significantly downregulated the phosphorylation of EGFR (Y1068 and Y1148), HER2 (Y1248) and HER3 (Y1289); among other receptor tyrosine kinases, it reduced the activation levels of cKit, Met and ALK, indicating that hMENA 11a plays a critical role in sustaining the activation of different oncogenic signals. A number of survival proteins, such as survivin, were downregulated by hMENA 11a silencing, while proteins such as H2AX and the cleaved forms of PARP and CASP9, all features of the apoptotic process, were upregulated. Overall, these RPPA data evidence a crucial role of hMENA 11a in sustaining signaling pathways related to cell proliferation and survival.
NRG-1 promotes hMENA 11a overexpression and phosphorylation, 15 thus we performed RPPA analysis on MDA-MB-361 cells (si-CNTR and si-hMENA 11a ) after NRG-1 treatment. A strong increase of Figure 1a) , suggesting that NRG-1 preferentially elicits HER3 and downstream targets AKT (S473) and p70S6K (T389) phosphorylation. Of note, NRG-1 treatment also increased insulin receptor substrate 1 (IRS1) phosphorylation, as previously reported for ER+ BC cell lines. 21 Differently, as evidenced in the heatmap (Figure 1a) , hMENA 11a silencing impairs NRG-1-mediated activation of the HER3/AKT axis. These results were validated by western blot (WB) (Figure 1b) .
When we assessed whether HER3 could reciprocally affect hMENA 11a expression, we evidenced that HER3 silencing does not affect hMENA 11a expression either in MDA-MB-361 or in MCF7 cells transfected with HER2 (MCF7-HER2) (Supplementary Figure 2) .
Overall, phospho-proteomic analysis and its WB validation revealed that hMENA 11a sustains HER3 activation and its downstream, pro-survival AKT pathway, suggesting a role for this hMENA isoform in survival and proliferation signals.
hMENA 11a expression correlates with HER3 expression and phosphorylation in HER2-overexpressing BC patients To investigate whether the strong correlation between hMENA 11a and HER3 activation evidenced by RPPA analysis occurs also in vivo, hMENA 11a isoform expression was evaluated by immunohistochemistry in parallel with HER3 and Y1289 P-HER3 antibodies in a series of 49 HER2-positive invasive ductal breast carcinomas consecutively selected from the surgical pathology files of the Regina Elena National Cancer Institute (Rome, Italy) with the approval of the Ethical Committee and written informed consent obtained from all patients. Clinicopathologic information of patients is listed in Supplementary Table 4 .
Ninety-five percent of cases showing a 2+, 3+ P-HER3 score (for representative scores, see Supplementary Figure 3 ) were concomitantly positive for hMENA 11a (P ⩽ 0.0001), evidencing a strong correlation between hMENA 11a and HER3 activation (Table 1 ). Although to a lesser extent, HER3 expression also correlates with hMENA 11a expression (P = 0.008) (data not shown). A phosphorylated status of HER3 was evidenced in 61% of the 31 HER3-positive cases (Supplementary Table 5 ). Representative cases stained with hMENA 11a , HER3 and P-HER3 antibodies are reported in Figure 2 .
Of note, cases which evidence a strong HER3 phosphorylation (score 2+, 3+) show an intense membranous staining of hMENA 11a , whereas, when P-HER3 is negative or low scored (score 0, 1+), staining of hMENA 11a is diffuse and cytoplasmic, leading us to hypothesize that the hMENA 11a relocalization is suggestive of a still to be elucidated function, related to HER3 activation. These in vivo results indicate that hMENA 11a overexpression is associated with HER3 activation in BC tissues and may represent a useful marker of HER3 activity. hMENA 11a silencing impairs HER3 activation and FOXO3a-mediated HER3 upregulation induced by PI3K inhibitors Given the critical role of HER3 in drug resistance and in treatment failure of PI3K inhibitors, 7 we investigated whether hMENA 11a is involved in the mechanisms of HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing BC cells. To test this hypothesis, MCF7-HER2 cells harboring constitutive activation of PI3K (E545K PIK3CA) were specifically silenced for hMENA 11a and treated with the dual PI3K/mTOR inhibitor BEZ235. 22 WB analyses showed that HER3 and AKT were constitutively active in MCF7-HER2 control cells (si-CNTR) ( Figure 3a ). hMENA 11a silencing reduced P-HER3 and P-AKT levels without affecting their expression. As expected, treatment with BEZ235 (24 h) completely inhibited P-AKT and P-S6. Consistent with previous reports, 4,7 the drug upregulated HER3 expression and activation. However, when the cells were silenced for hMENA 11a , the effect of BEZ235 treatment on HER3 was impaired ( Figure 3a Figure 4b) . The HER3 mRNA upregulation mediated by PI3K inhibition was impaired by hMENA 11a silencing, whereas no effect was evident in untreated cells (Figure 3b ), in agreement with data at protein level.
PI3K inhibitors increase HER3 transcription through deregulation of the transcription factor FOXO3a. 5, 24 FOXO3a nuclear translocation is impaired by AKT-mediated phosphorylation, whereas downregulation of P-AKT due to PI3K inhibition results in FOXO3a nuclear accumulation and increase of HER3 transcription.
5,24
Thus, we asked whether hMENA 11a overexpression may affect FOXO3a subcellular localization by analyzing MCF7-HER2 control cells (si-CNTR) and hMENA 11a -silenced cells (si-hMENA 11a ) untreated or BEZ235-treated. In the majority of the untreated cells, FOXO3a was simultaneously found in both nucleus and cytoplasm, and hMENA 11a silencing did not modify FOXO3a localization ( Figure 3c ). As expected, BEZ235 treatment resulted in FOXO3a nuclear accumulation in 85% of si-CNTR cells followed by HER3 mRNA upregulation (Figures 3d and b) . Differently, hMENA 11a silencing impaired BEZ235-mediated FOXO3a nuclear accumulation (Figure 3c ). Only 29% of cells showed a FOXO3a nuclear localization (Figure 3d ). Similar results were obtained in MDA-MB-361 cells by using three different PI3K inhibitors (Supplementary Figure 4c) .
These immunofluorescence results were confirmed by biochemical experiments on fractionated cell lysates evidencing that nuclear accumulation of FOXO3a upon BEZ235 treatment was impaired in silenced hMENA 11a cells, at 24 h and even at short incubation (6 h) (Figure 3e ). Taken together, these data suggest that hMENA 11a sustains the PI3K inhibition-mediated HER3 upregulation, at least in part, by allowing FOXO3a nuclear accumulation.
PI3K inhibitor treatment affects hMENA 11a phosphorylation and localization To investigate the functional role of hMENA 11a in the compensatory pathways involved in the resistance to PI3K inhibitors, we analyzed whether BEZ235 treatment affects hMENA 11a expression levels and we found that the treatment does not modify hMENA 11a expression levels ( Figure 4a ). However, immunofluorescence analysis evidenced a different subcellular localization of hMENA 11a in the untreated (CNTR) vs PI3K inhibitor-treated cells. A diffuse cytoplasmic pattern of 25 showed that the inhibitor determined a shift of hMENA 11a spots toward an acidic pH, a pattern reminiscent of that previously reported for hMENA 11a phosphorylation induced by EGF or NRG-1 stimulation (Figure 4c ). hMENA 11a sustains cancer cell proliferation, survival and resistance to HER3-mediated PI3K inhibition Results that hMENA 11a overexpression might affect AKT-related pro-survival signaling pathways prompted us to verify the role of hMENA 11a overexpression at the functional level. We stably transfected hMENA 11a in DAL (thereafter called DAL11a), a breast cancer cell line with undetectable expression of any of the hMENA isoforms. 26 In DAL11a, the P-HER3 levels were increased, confirming a link between hMENA 11a and HER3 activation in BC cells (Figure 5a ). Of note, the hypothesis that only the epithelial hMENA 11a isoform is linked to HER3 signaling was confirmed by transfecting DAL cells with the mesenchymal-related hMENAΔv6 isoform 20 that did not affect HER3 activation levels (Figure 5b ). To evaluate whether hMENA 11a overexpression affects cell proliferation and survival in response to BEZ235 treatment, we evaluated dose-response curves in DAL and DAL11a cells. hMENA 11a overexpression determined a shift in BEZ235 IC50 from 67 nM in DAL compared with 111 nM in DAL11a after 72 h of treatment, indicating that hMENA 11a may be crucial in the resistance of BC cells to BEZ235 treatment (Figure 5c ).
We further evaluated cell cycle distribution by flow cytometry. hMENA 11a silencing impacted on cell proliferation of both MDA-MB-361 and MCF7-HER2, decreasing the percentage of cells in the S phase and increasing those in the G1 phase of the cell cycle (Figure 6a ). In agreement with previous observations, 27 BEZ235 treatment resulted in an accumulation of cells in the G1 phase compared with the untreated controls (Figure 6a ). Of relevance, the combination of hMENA 11a silencing and BEZ235 treatment further decreased the percentage of cells in the S phase (Figure 6a ) and induced the accumulation of a sub-G1 peak (Figure 6b, upper panel) , suggestive of cell death. These data were confirmed by 3 H-thymidine incorporation assay (Supplementary Figure 5) .
To evaluate whether the accumulation of cells in the sub-G1 peaks was due to the induction of apoptosis, we assessed the PARP cleavage, and as shown in Figure 6b lower panel, hMENA 11a has a role in apoptosis as evidenced by the full length and cleaved pattern of PARP.
Tumors bearing high levels of the Bcl-2 family member BIM are more susceptible to PI3K inhibitor-mediated apoptosis and BIM has been proposed as a biomarker of apoptosis sensitivity. 28 In agreement with published results, 29 BEZ235 treatment did not increase BIM in either of the cell lines evaluated. Interestingly, at least in MDA-MB-361 cells, hMENA 11a silencing determined an increase in BIM levels (Figure 6b ), indicating that hMENA 11a exerts an anti-apoptotic role and affects BIM expression.
hMENA 11a sustains cancer cell resistance to PI3K inhibition in three-dimensional (3D) cultured BC cells It is becoming increasingly evident that 3D cultures better reflect drug sensitivity in vivo.
30,31 Thus, we cultured MCF7-HER2 control This 3D analysis confirms the above-reported results with twodimensional (2D) cultures and supports the data showing that hMENA 11a silencing reduces cell proliferation and sensitizes cells to PI3K inhibition.
DISCUSSION
The actin cytoskeleton architecture impacts many cellular processes and signaling pathways associated with cancer. 11 hMENA, an actin regulatory protein, undergoes splicing, and our group has described two alternatively expressed isoforms, hMENA 11a and hMENAΔv6, with opposite functions in cancer cell invasion. 20 hMENA 11a is phosphorylated downstream of HER2 and EGFR after treatment with NRG-1 and EGF. hMENA 11a cooperates with mitogenic signaling of the ErbB family receptors, and when hMENA and HER2 are both overexpressed, patients have a worse prognosis. 15 The role of hMENA 11a in oncogenic signaling pathways has been poorly investigated and the kinase involved in hMENA 11a phosphorylation has not yet been identified. Herein, we present data suggesting that the overexpression of the epithelialassociated hMENA 11a isoform is correlated with HER3 overexpression and phosphorylation in HER2-positive tumors, is crucial for sustaining pro-survival pathways and participates in HER3 activation, influencing resistance mechanisms to PI3K/mTOR targeted therapies.
The success in obtaining specific hMENA 11a isoform silencing allowed us to demonstrate that this isoform sustains different receptor tyrosine kinase signaling pathways. In particular, as evidenced by RPPA, in HER2-overexpressing BC cells, hMENA 11a sustains the activation of ErbB family receptors, as evidenced by the downregulation of P-EGFR, P-HER2 and P-HER3 after specific silencing of this isoform. Even though the mechanisms involved still need to be elucidated, the results of RPPA suggest that hMENA 11a is critical in sustaining the activation of relevant pathways involved in cell proliferation and apoptosis, as 11a and treated with NRG-1. hMENA 11a silencing counteracts the NRG-1-mediated activation of different key molecules, including IRS1, reported to be recruited to HER3 following NRG-1 treatment. 21 Of note, the phosphorylation of IRS1 provides docking sites for the recruitment of key signaling pathways. 21, 33 Interestingly, we found that NRG-1 was unable to activate HER3 signaling in cells lacking hMENA 11a , suggesting a critical role of hMENA 11a in HER3/AKT axis activation. This is relevant when considering the highlighted role of HER3 signaling in HER2-amplified BC cells.
Expression and signaling functions of HER3 are highly regulated through a multitude of mechanisms at the transcriptional, translational and posttranslational levels. 34 Our data, showing that hMENA 11a silencing decreases HER3 phosphorylation levels without influencing the RNA and protein levels, support the hypothesis that hMENA 11a may participate in a posttranslational mechanism accounting for HER3 signaling activation without inducing the expression. At the moment, it is difficult to speculate on these findings. However, we can hypothesize that hMENA 11a may participate in the highly dynamic nature of this HER family member, by affecting its localization and trafficking. Recently Vehlow et al. 35 reported that MENA cooperates with Lamellipodin and Endophilin to regulate F-actindependent EGFR endocytosis.
Of clinical relevance, our immunohistochemical results clearly support experimental data and for the first time, highlight the correlation among hMENA 11a , HER3 activation and expression in HER2-overexpressing breast tumors. Although further studies are needed, we hypothesize that hMENA 11a and its phosphorylation, affected by different growth factors, are relevant in the activation of the HER2/HER3 oncogenic unit.
Multiple studies have implicated the functions of HER3 as a major cause of treatment failure to targeted therapies and HER3 upregulation and activity have been proposed as a major compensatory feedback mechanism occurring after PI3K inhibition in HER2-overexpressing cell lines. 5, 6, 36 Thus, we compared the effects of different PI3K inhibitors in HER2-overexpressing cell lines with respect to hMENA 11a silenced cells. Notably, results at the RNA and protein levels highlight the role of hMENA 11a in sustaining HER3 expression induced by PI3K inhibition. Indeed, silencing of hMENA 11a was able to counteract the known compensatory effect of HER3 expression and activation exerted by the dual mTOR/PI3K inhibitor BEZ235. From a mechanistic point of view, downstream to PI3K inhibition, AKT when inhibited recruits the transcription factor FOXO3a to the HER3 promoter enabling HER3 expression. 5, 24 Of note, we have found that FOXO3a nuclear accumulation determined by PI3K inhibition was impaired by hMENA 11a silencing, with a crucial effect on HER3 transcription. The FOXO3a subcellular localization depends on the dynamic interactions with the Protein Phosphatase 2A (PP2A) and the scaffold proteins 14-3-3. 37 After inhibition of PI3K, the FOXO3a phosphorylation is no longer favored and PP2A and FOXO3a translocate into the nucleus after dissociation from 14-3-3. 37 Of relevance, as evaluated by ELM (Eukaryotic Linear Motifs) server (http://elm.eu.org/), 38 the hMENA 11a sequence has four interacting motifs for 14-3-3, known to participate at the regulation of cytoskeleton. 39 Two out of the four motifs identified in silico are phospho-motifs present only in the 11a isoform, being located in the 21 aa sequence of the 11a peptide. Further studies, validating this predictive binding between hMENA 11a and 14-3-3, will provide evidence supporting the hypothesis that hMENA 11a via 14-3-3 binding may affect FOXO3a nuclear localization. Hence, the overexpression of this isoform and above all, its phosphorylation status may affect relevant molecular complexes involved in the transcription of HER3. hMENA 11a amino-acid residues that are phosphorylated by growth factors 15, 16 have not yet been identified. Also, the kinase involved is yet to be identified. The 2D electrophoresis analysis clearly showed that PI3K inhibitor treatment, which does not affect hMENA 11a expression, induces phosphorylation of hMENA 11a , which in turn shifts its localization from the cytoplasm to the membrane. Consistent with these results, it has been recently reported that several of the phosphoproteins activated by PI3K pathway inhibitors are related to cytoskeletal reorganization and are proposed as candidate pharmacodynamic biomarkers for PI3K/AKT/mTOR drug development. 40 Although the mechanisms have to be further elucidated, our results suggest that hMENA 11a overexpression and phosphorylation affect the HER3 phosphorylation and expression by mechanisms that are independent of each other. HER2 is the main kinase responsible for HER3 activation occurring after PI3K inhibition in HER2-overexpressing BC cells, 4 and we have previously reported that Trastuzumab treatment downregulates hMENA 11a expression and phosphorylation, 15 thus, suggesting that hMENA 11a overexpression and phosphorylation may sustain the HER2/HER3 dimer.
Recently, actin-binding proteins have been proposed as sensors and mediators of apoptosis, and remodeling of the actin cytoskeleton may enable tumor cells to escape normal apoptotic signaling. 41 No data are available on the role of hMENA or its isoforms in apoptotic processes, although we have previously reported that hMENA 11a overexpression favors the proliferation rate of BC cells. 16 Our findings are consistent with the hypothesis that hMENA 11a sustains an anti-apoptotic signaling in BC cells. Of clinical relevance, hMENA 11a overexpression increases the resistance of BC cells to BEZ235 treatment, whereas its silencing sensitizes cells to BEZ235-induced death. Furthermore, the results that the hMENA 11a silencing reduces the expression of the proapoptotic Bcl-2 family member BIM, 42 critical mediator of targeted therapy-induced apoptosis, 28 corroborate the hypothesis that hMENA 11a promotes a survival advantage in BC cells. The 3D models better recapitulate signaling pathways related to proliferation and survival 43 and have been reported as relevant systems to study cancer cell resistance to PI3K/mTOR inhibition. 44 Our monolayer culture results were validated in 3D, enforcing the role of hMENA 11a in mechanisms of resistance to the dual inhibitor BEZ235.
Although further studies are required, our results hold promise for multi-fold clinical implications. We can speculate that hMENA 11a expression may be proposed as a marker of HER3 activity, which lacks validated specific markers hampering the progress of HER3-targeted therapy. 45 Moreover, the specific expression of this hMENA isoform in combination with BIM may permit the selection of patients less likely to respond or those who may derive maximal benefit from therapies including PI3K/mTOR inhibitors. There is hope that the identification of drugs able to shut down hMENA 11a activity may lead to the design of more effective antiproliferative therapies in BC.
MATERIALS AND METHODS

Cell lines and treatments
The human breast carcinoma cell lines MDA-MB-361 and MCF7 were obtained from the ATCC; MCF7-HER2 stable transfectants were obtained as previously described. 15 DAL cell line, DAL11a and DALΔv6 transfectants were obtained as previously reported. 20, 46 All cell lines were routinely tested for ER status, morphologically checked by microscope, growth curve analysis by 3H-Thymidine incorporation assay and Mycoplasma detection (Roche, Monza, Italy).
NRG-1 (PeproTech, Rocky Hill, NJ, USA) was added to serum-starved cells at a concentration of 10 ng/ml. BEZ235 (0.5 μM, Selleck Chemicals, Houston, TX, USA), XL147 (20 μM, Selleck Chemicals) and LY294002 (10 μM, Cell Signaling Technology, Danvers, MA, USA) were used.
Small-interfering RNA (siRNA) treatment Cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) with 100 nmol/l of ON-TARGETplus Nontargeting Control Pool (GEHealthcare, Dharmacon, Lafayette, CO, USA), or HER3 siRNA. Specific hMENA 11a silencing was performed by transfecting cells with a mix of three siRNAs (30 pmol each) each matching 21 nucleotides within the 11a exon sequence. The siRNAs sequences used are reported in Supplementary  Table 6 .
For NRG-1 stimulation, 24 h after the transfection, cells were serumstarved for 18 h and then treated with NRG-1; for PI3K inhibitor treatments, 48 h after the transfection, cells were treated with XL147 in 2.5% serum containing medium or with BEZ235 or LY294002 in complete medium. Cells were processed 72 h after the transfection.
Reverse phase protein array
Protein lysate preparation and RPPA were performed on biological triplicate samples, as previously reported. 47 Supplementary Table 1 reports detailed information concerning the antibodies used.
Spot intensity was analyzed by MicroVigene software V5.1 (VigeneTech, North Billerica, MA, USA), and normalized to total protein and standardized. RPPA data were subjected to unsupervised statistical analysis (average method) using JMP V10.0.2 (SAS Institute, Cary, NC, USA). Statistically significant endpoints were evaluated using the multiple comparison Dunnett's test. P valueso 0.05 were considered significant. The lists of total significant and nonsignificant endpoints were reported in Supplementary Tables 2 and 3. WB analysis WB was performed as reported. 15 Nuclear and cytoplasmic fractions were prepared using NE-PER Nuclear Cytoplasmic Extraction Reagent kit (Pierce, Rockford, IL, USA). Anti-hMENA 11a , pan-hMENA and hMENAΔv6 were used as already described. 14, 15, 20 Anti-HER3 #12708, P-HER3 (Y1289) #4791, P-AKT (S473) #4060, AKT #4685, P-S6 (S240/244) #2215, S6 #2217, BIM #2819, PARP #9542 (Cell Signaling Technology), anti H3 #Ab-1791 (Abcam, Cambridge, UK), anti-β actin #A4700 (Sigma-Aldrich, Poole, UK), HSP70 #sc-24 (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA), anti-FOXO3a #04-1007 (EMD Millipore Corporation, St Charles, MO, USA) were used. Immunohistochemistry HER2, ER, PgR and Ki67 status and hMENA 11a expression were assessed on tissues from 49 HER2-positive BC patients as previously reported.
20 HER3 (#NCL-cerbB-3, Novocastra Leica, Menarini, Florence, Italy) and P-HER3 (Cell Signaling Technology) antibodies were used. For HER3, P-HER3 and hMENA 11a , an immunohistochemistry (IHC) score of 2/3 on the membrane or cytoplasm was defined as positive. For statistical analysis, negative (score 0/1) and positive (score 2/3) groups were created. Evaluation of the IHC results was performed independently by two investigators (MM, ADB) blinded to patient data.
RNA extraction and real-time PCR
Total RNA extraction and cDNA synthesis were performed as reported.
20
HER3 primers used were: 5′-GGGGAGTCTTGCCAGGAG-3′ and 5′-CATTGGGTGTAGAGAGACTGGAC-3′. GAPDH primers were used as an internal control. qRT-PCR was performed with 10 ng cDNA in ABI Prism 7900 Real-time PCR system using SYBR Green PCR Master Mix (Applied Biosystems, Princeton, NJ, USA). Gene expression was calculated using the equation 2 − ΔΔCt . 48 
Immunoflorescence
Cells transfected with siRNAs and/or treated with PI3K inhibitors were fixed and permeabilized as previously described. 20 Cells were stained with anti-hMENA 11a and/or anti-FOXO3a antibodies. Nuclei were stained with 4'6-diamidino-2-phenylindole (Invitrogen). Immunofluorescence was analyzed by Leica DM IRE2 microscopy with Leica FW 4000 software (Leica, Solms, Germany).
2D electrophoresis
2D electrophoresis was performed as previously described. 15 hMENA 11a and PI3K inhibitors in breast cancer P Trono et al
Crystal violet assay
Cells (5 × 10 4 ) seeded in triplicates in 24-well plates were treated with increasing doses of BEZ235 for 72 h. Cells were fixed with 4% formaldehyde and stained with 0.1% crystal violet (Sigma). The dye was subsequently extracted with 10% acetic acid, its absorbance was determined (570 nm) and the percentages of surviving cells relative to control, defined as 100% survival, were reported. IC50 values were calculated by Calcusyn software. ) were seeded on top of a growth factor reduced reconstituted basement membrane Matrigel (BD Pharmingen) containing 5% (vol/vol) laminin-rich extracellular matrix and plated in six-well plates for live/dead assay or into an eight-well plastic-chambered glass microscope slide (Thermo Scientific Nunc Lab-Tek II Chamber Slide System, Thermo Fisher Scientific, Waltham, MA, USA) for IHC. The day after, 0.5 μM BEZ235 was added for 48 h. For live/dead assay, cells were incubated for 30 min at 37°C with 100 μM calcein AM (Invitrogen) and 0.1 μg/ml 4'6-diamidino-2-phenylindole to stain viable and nonviable cells, respectively. Intensity of fluorescence was assessed as reported above. For IHC, 3D cell cultures were processed as previously reported 49 and immunostained with hMENA 11a and Ki67 (#M724001, DAKO, Milan, Italy) antibodies.
Statistical analysis
All experiments were repeated a minimum of three times. Data are expressed as the mean ± s.d. Statistical significance was determined by Student's t test (two-tailed) comparison between two groups of datasets, with similar variance. Asterisks indicate significant differences of experimental groups compared with the corresponding control condition (Po 0.05). To assess the relationship between categorical variables, Fisher's exact text was used when appropriate. A P value of o0.05 was considered statistically significant. To calculate the sample size for immunohistochemical study, we based on the percentage of HER2/HER3 positivity with respect to hMENA 11a expression in BC cell lines. 20, 50 The proportion of HER2/HER3 positivity was equal to 80% in hMENA 11a -positive BC and 40% in hMENA 11a -negative BC. Applying a two-sided Z-test with pooled variance, assuming a statistical power equal to 80% and a significance level equal to 0.05, we needed to recruit a minimum of 46 patients. Statistical analyses were carried out using SPSS software (SPSS version 21, SPSS Inc., Chicago, IL, USA). The data presented in some figures are from a representative experiment, which was qualitatively similar in the replicate experiments.
